Facing various difficulties encountered in clinical practice, doctors often come up with brilliant "golden ideas". Every year, many clinical medical innovations with academic value emerge, but declaring these clinical innovations as patent achievements and transforming them will consume a lot of time and energy from doctors. How to transform research results quickly and effectively in the laboratory into products that truly benefit patients?

The fourth Fudan Patent Salon was held on December 21, 2023 at Zhongshan Hospital affiliated to Fudan University to enhance the enthusiasm of doctors and researchers for invention and innovation, promote the "first mile" of clinical innovation, and promote the integration of industry and medicine.

Fan Jia, an academician of CAS, president of the Zhongshan Hospital affiliated to Fudan University, and Zhou Jian, vice president of the Zhongshan Hospital affiliated to Fudan University, jointly signed a contract with the patent transferee on behalf of the hospital. Dunwill Medical's subsidiaries——Shanghai Epione Medlab and Jusbio Sciences (Shanghai) Co., Ltd. held a signing ceremony for multiple patent conversion projects with Zhongshan Hospital. Ms. Sofia Wen, Chairman and Founder of Dunwill Medical, Ms. Lu Binbin, General Manager of Epione Medlab, and Mr. Liu Zhanjie, General Manager of Jusbio Sciences, attended the signing ceremony as company representatives.

In the subsequent report sharing session, Mr. Hou Ying, Executive Director of Dunwill Medical Marketing & Strategic Development Center, brought a excellent report titled "Dunwill Medical: Willingly to Be the Transformation Ladder of Original Biomarker of Zhongshan Hospital". He introduced Dunwill Medical's ability to empower clinical transformation and its unique multi-platform integration ability. Starting from identifying clinical needs and pain points, Dunwill can work with clinical experts to study the mechanisms of complex disease occurrence and development, select the most suitable clinical transformation path, and promote the formation of original clinical grade IVD products with independent intellectual property rights. The advantages of Dunwill's transformation empowerment are reflected in its more comprehensive clinical research support capabilities, more flexible selection of in vitro diagnostic product conversions, and more experienced application of original research products.

Dunwill and Zhongshan Hospital have rich cooperation experience. The first international miRNA liver cancer test kit, miRNA7^TM, jointly developed by Dunwill and Zhongshan Hospital, is also the first liver cancer molecular detection product approved by the National Medical Products Administration (NMPA). The market access has covered more than 20 provinces in China, and the testing volume in the country is expected to reach 800000 by the end of the year.

Mr. Hou Ying further introduced Dunwill’s Medical Patent Transformation Cooperation Mechanism. Through the cooperation model of "comprehensive commercial evaluation - overall patent valuation - transaction structure design - negotiation and signing execution", key areas and aspects can be anchored, allowing more scientific research achievements to be transformed and creating more patent products suitable for patients.

Dunwill's vision is to become a ladder for hospitals to transform their original research biomarkers and a paving stone for them to enter the Chinese and global markets. The integration of industry and medicine is becoming a key path for medical innovation nowdays. The combination of industry power and medical care will bring broader markets and richer resources; "Bidirectional cooperation" enables both parties to achieve complementary advantages and promote innovative cooperation projects. Looking forward to more innovative achievements being implemented one by one in the near future, benefiting more patients in clinical diagnosis and treatment services.